Forfivo™ Traction Expected To Accelerate. We note that Forfivo™ has now been available in the U.S. for roughly six months, and that IntelGenx's partner Edgemont Pharmaceuticals appears to have dealt with most of the initial snags that impacted the launch of the drug. Accordingly, therefore, we anticipate meaningful acceleration in Forfivo™ prescription volumes in the coming months. While we do not expect the drug to become a massive seller, we note that even a relatively modest revenue base would likely have substantial impact on IntelGenx's bottom line, and should be sufficient to drive the company towards profitability. We note that IntelGenx continues to exhibit a cost-effective operational approach, burning roughly $2mm or less per year. We reiterate our Buy rating and 18-month price target of $3.00 per share on IGXT.